Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus placebo Critical...
Hence then, the article about published in the lancet nipocalimab significantly decreased sjogren s disease sjd activity and severity through substantial reduction in sjogren s related autoantibodies was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies )
Also on site :
- Rochester man accused of raping 15 year old who State Police say he met online
- Stassi Schroeder Opens Up on Her Modern Marriage Role Reversal and 'Mr. Mom' Husband Beau Clark (Exclusive)
- When Will 'Spider-Man: Brand New Day' Be Streaming? Everything We Know So Far